Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

NCT05731752 is registered in ClinicalTrials.gov with Hangzhou Hanx Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT05731752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05731752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 28, 2020
Completion date
December 30, 2024
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors